Article
Adjuvant epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) for the treatment of people with resected stage I to III non-small-cell lung cancer and EGFR mutation.
The Cochrane database of systematic reviews - 27 May 2025
Occhipinti Mario, Imbimbo Martina, Ferrara Roberto, Simeon Vittorio, Fiscon Giulia, Marchal Corynne, Skoetz Nicole, Viscardi Giuseppe
Abstract excerpt
BACKGROUND: Postoperative adjuvant epidermal growth factor receptor (EGFR) inhibitor osimertinib is the standard care for stage IB-IIIB non-small-cell lung cancer (NSCLC) with EGFR exon 19 deletions or exon 21 L858R mutation, following complete tumour resection, with or without prior platinum-based adjuvant chemotherapy. However, the role of EGFR tyrosine kinase inhibitors (TKIs) in this setting is debated,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.